Review



v-plex covid-19 ace2 neutralization kits  (Meso Scale Diagnostics LLC)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Meso Scale Diagnostics LLC v-plex covid-19 ace2 neutralization kits
    V Plex Covid 19 Ace2 Neutralization Kits, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/pm39993812__ja4c15843_si_001-217-211-204
    Average 90 stars, based on 1 article reviews
    v-plex covid-19 ace2 neutralization kits - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Neutralization:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Blocking Assay:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Binding Assay:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Variant Assay:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    SYBR Green Assay:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Software:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Infection:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Clinical Proteomics:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Enzyme-linked Immunosorbent Assay:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Enzyme-linked Immunospot:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Luciferase:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).

    Recombinant:

    Article Title: mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Article Title: Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients.
    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 andvariant spike subdomains).



    Similar Products

    v-plex covid-19 ace2 neutralization kits  (Meso Scale Diagnostics LLC)
    90
    Meso Scale Diagnostics LLC v-plex covid-19 ace2 neutralization kits
    V Plex Covid 19 Ace2 Neutralization Kits, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/pm39993812__ja4c15843_si_001-217-211-204
    Average 90 stars, based on 1 article reviews
    v-plex covid-19 ace2 neutralization kits - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    v-plex covid-19 ace2 neutralization assay kits panel 29 [ace2] kit, k15672u  (Meso Scale Diagnostics LLC)
    90
    Meso Scale Diagnostics LLC v-plex covid-19 ace2 neutralization assay kits panel 29 [ace2] kit, k15672u
    V Plex Covid 19 Ace2 Neutralization Assay Kits Panel 29 [Ace2] Kit, K15672u, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/pmc11091345-104-13-25
    Average 90 stars, based on 1 article reviews
    v-plex covid-19 ace2 neutralization assay kits panel 29 [ace2] kit, k15672u - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    v-plex® covid-19 ace2 neutralization kits panel 20  (Meso Scale Diagnostics LLC)
    90
    Meso Scale Diagnostics LLC v-plex® covid-19 ace2 neutralization kits panel 20
    ( A ) Schema of vaccine trial design. ( B ) Graph of mean body weight, in grams, of each group of animals on days 42, 43, 44, 45, and 46, +/− (whiskers) standard error of the mean (s.e.m.). Orange, 10x vaccine group; blue, 1x vaccine group, black, 10x control exosomes group. Data was interrogated by 2-way ANOVA with Bonferroni’s multiple comparisons, with * and **denoting p values < 0.05 and <0.05, respectively. ( C ) Levels of infectious SARS-CoV-2 virus in cranial lung at day 46, +/− s.e.m. (whiskers). Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. ** and *** denote p values < 0.005 and 0.0005, respectively. ( D ) Neutralizing activity of plasma samples against SARS-CoV-2 virus, plotted as log10 area under the curve (AUC) for day 46 plasmas. Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. * and **** denote p values < 0.05 and <0.0001, respectively. ( E ) Inhibition of <t>ACE2</t> binding to immobilized spike (B.1.617.2) by plasmas collected at days −7, 21, 35, and 46, diluted 1:40. ( F ). Inhibition of ACE2 binding to immobilized spike proteins by plasmas collected at days 46, diluted 1:40. Spike proteins were from delta (B.1.617.2), WT (Wuhan-1), alpha (B.1.1.7), beta (B.1.351) and omicron (BA.1, BA.5, and XBB.1) strains of SARS-CoV-2.
    V Plex® Covid 19 Ace2 Neutralization Kits Panel 20, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/bio_rxiv__2024__01__04__574272-183-1-16
    Average 90 stars, based on 1 article reviews
    v-plex® covid-19 ace2 neutralization kits panel 20 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    v-plex covid-19 ace2 neutralization kit panel 18 [ace2] kit k15570u  (Meso Scale Diagnostics LLC)
    90
    Meso Scale Diagnostics LLC v-plex covid-19 ace2 neutralization kit panel 18 [ace2] kit k15570u
    ( A ) Schema of vaccine trial design. ( B ) Graph of mean body weight, in grams, of each group of animals on days 42, 43, 44, 45, and 46, +/− (whiskers) standard error of the mean (s.e.m.). Orange, 10x vaccine group; blue, 1x vaccine group, black, 10x control exosomes group. Data was interrogated by 2-way ANOVA with Bonferroni’s multiple comparisons, with * and **denoting p values < 0.05 and <0.05, respectively. ( C ) Levels of infectious SARS-CoV-2 virus in cranial lung at day 46, +/− s.e.m. (whiskers). Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. ** and *** denote p values < 0.005 and 0.0005, respectively. ( D ) Neutralizing activity of plasma samples against SARS-CoV-2 virus, plotted as log10 area under the curve (AUC) for day 46 plasmas. Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. * and **** denote p values < 0.05 and <0.0001, respectively. ( E ) Inhibition of <t>ACE2</t> binding to immobilized spike (B.1.617.2) by plasmas collected at days −7, 21, 35, and 46, diluted 1:40. ( F ). Inhibition of ACE2 binding to immobilized spike proteins by plasmas collected at days 46, diluted 1:40. Spike proteins were from delta (B.1.617.2), WT (Wuhan-1), alpha (B.1.1.7), beta (B.1.351) and omicron (BA.1, BA.5, and XBB.1) strains of SARS-CoV-2.
    V Plex Covid 19 Ace2 Neutralization Kit Panel 18 [Ace2] Kit K15570u, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/10__26502_slash_ami__936500136-117-50-51
    Average 90 stars, based on 1 article reviews
    v-plex covid-19 ace2 neutralization kit panel 18 [ace2] kit k15570u - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    v-plex covid-19 ace2 neutralization kit  (Meso Scale Diagnostics LLC)
    90
    Meso Scale Diagnostics LLC v-plex covid-19 ace2 neutralization kit

    V Plex Covid 19 Ace2 Neutralization Kit, supplied by Meso Scale Diagnostics LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/v-plex+covid-19+ace2+neutralization+kit/v+plex+sars+cov+2+panel+2+kit/pmc09561373-192-1-6
    Average 90 stars, based on 1 article reviews
    v-plex covid-19 ace2 neutralization kit - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Schema of vaccine trial design. ( B ) Graph of mean body weight, in grams, of each group of animals on days 42, 43, 44, 45, and 46, +/− (whiskers) standard error of the mean (s.e.m.). Orange, 10x vaccine group; blue, 1x vaccine group, black, 10x control exosomes group. Data was interrogated by 2-way ANOVA with Bonferroni’s multiple comparisons, with * and **denoting p values < 0.05 and <0.05, respectively. ( C ) Levels of infectious SARS-CoV-2 virus in cranial lung at day 46, +/− s.e.m. (whiskers). Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. ** and *** denote p values < 0.005 and 0.0005, respectively. ( D ) Neutralizing activity of plasma samples against SARS-CoV-2 virus, plotted as log10 area under the curve (AUC) for day 46 plasmas. Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. * and **** denote p values < 0.05 and <0.0001, respectively. ( E ) Inhibition of ACE2 binding to immobilized spike (B.1.617.2) by plasmas collected at days −7, 21, 35, and 46, diluted 1:40. ( F ). Inhibition of ACE2 binding to immobilized spike proteins by plasmas collected at days 46, diluted 1:40. Spike proteins were from delta (B.1.617.2), WT (Wuhan-1), alpha (B.1.1.7), beta (B.1.351) and omicron (BA.1, BA.5, and XBB.1) strains of SARS-CoV-2.

    Journal: bioRxiv

    Article Title: Antigen-display exosomes provide adjuvant-free protection against SARS-CoV-2 disease at nanogram levels of spike protein

    doi: 10.1101/2024.01.04.574272

    Figure Lengend Snippet: ( A ) Schema of vaccine trial design. ( B ) Graph of mean body weight, in grams, of each group of animals on days 42, 43, 44, 45, and 46, +/− (whiskers) standard error of the mean (s.e.m.). Orange, 10x vaccine group; blue, 1x vaccine group, black, 10x control exosomes group. Data was interrogated by 2-way ANOVA with Bonferroni’s multiple comparisons, with * and **denoting p values < 0.05 and <0.05, respectively. ( C ) Levels of infectious SARS-CoV-2 virus in cranial lung at day 46, +/− s.e.m. (whiskers). Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. ** and *** denote p values < 0.005 and 0.0005, respectively. ( D ) Neutralizing activity of plasma samples against SARS-CoV-2 virus, plotted as log10 area under the curve (AUC) for day 46 plasmas. Data was analyzed by one way ANOVA with Tukey’s multiple comparisons. * and **** denote p values < 0.05 and <0.0001, respectively. ( E ) Inhibition of ACE2 binding to immobilized spike (B.1.617.2) by plasmas collected at days −7, 21, 35, and 46, diluted 1:40. ( F ). Inhibition of ACE2 binding to immobilized spike proteins by plasmas collected at days 46, diluted 1:40. Spike proteins were from delta (B.1.617.2), WT (Wuhan-1), alpha (B.1.1.7), beta (B.1.351) and omicron (BA.1, BA.5, and XBB.1) strains of SARS-CoV-2.

    Article Snippet: The V-PLEX® COVID-19 ACE2 Neutralization Kits Panel 20 (Cat#K15554U-2) and Panel 34 (Cat#K15693U-2) were purchased from Meso Scale Diagnostics (MSD), Rockville, MD USA.

    Techniques: Control, Virus, Activity Assay, Clinical Proteomics, Inhibition, Binding Assay

    Journal: iScience

    Article Title: Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients

    doi: 10.1016/j.isci.2022.105369

    Figure Lengend Snippet:

    Article Snippet: The V-PLEX COVID-19 ACE2 Neutralization kit (Meso Scale Discovery, Panel 23 (ACE2) Kit, K15570U) was used to quantitatively measure antibodies that block the binding of ACE2 to its cognate ligands (SARS-CoV-2 and variant spike subdomains).

    Techniques: SYBR Green Assay, Software